| Old Articles: <Older 2081-2090 Newer> |
|---|
 |
Financial Advisor
October 2012
Jerilyn Klein Bier |
Beyond The BRICs Investors see compelling opportunities in the next four largest growth markets. Equity funds dedicated to the MIST markets (Mexico, Indonesia, South Korea and Turkey) took in a net fund flow of $786 million during the six weeks ending August 31.   |
Chemistry World
October 2, 2012
Andrew Turley |
Merck & Co $460m ion channel deal Merck & Co has struck a $460 million deal for rights to certain drug candidates developed by Belgian pharma company Ablynx. Merck will get rights to the monoclonal antibodies found to target a voltage gated ion channel. |
Chemistry World
September 26, 2012
Andrew Turley |
Boehringer drops virology R&D German pharma company Boehringer Ingelheim is to close its R&D site in Laval, Canada, in early 2013, with the loss of 170 jobs. |
Chemistry World
September 24, 2012
Andrew Turley |
$100m of diabetes R&D in China Danish drug maker Novo Nordisk has announced plans to invest $100 million in its R&D site in Beijing, China. The move will create 130 -- 200 new research jobs. |
Chemistry World
September 18, 2012
Andrew Turley |
Bayer $145 million animal health deal Bayer has signed a $145 million deal to buy the US part of the animal health business at Israeli generics giant Teva. |
Commercial Investment Real Estate
Sep/Oct 2012 |
International Beat LaSalle Investment Management Kapitalanlagegesellschaft mbH recently purchased two retail properties in Scotland and despite Europe's economic woes, global investors continued to target select markets in the second quarter, according to Jones Lang LaSalle. |
CIO
September 14, 2012
Kim S. Nash |
Innovation Can Start Far From Home The needs of customers in emerging markets are far different than those of customers in the rich world. Innovations needed to meet the needs of customers in the developing world can flow uphill. |
Pharmaceutical Executive
September 1, 2012
Thomas Baker |
The Big Sell: Biologics In Emerging Markets High priced biologics may have a bright future in emerging markets, but winning access in the short term will be a hard sell without a tailored clinical profile, a compelling local message, and direct government support. |
CFO
September 1, 2012
Kathleen Hoffelder |
SEC Report Backs Away from Convergence The commission's staff expresses hesitation about merging international standards and U.S. GAAP. |
CFO
September 1, 2012
Marielle Segarra |
Business Is Sweet Godiva Chocolatier is enjoying double-digit growth, thanks in part to innovative chocolates and expansion in Asia, says CFO Dave Marberger. |
| <Older 2081-2090 Newer> Return to current articles. |
